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Cellular identity is established by genetic, epigenetic, and environmental factors that regulate organogenesis
and tissue homeostasis. Although some flexibility in fate potential is beneficial to overall organ health,
dramatic changes in cellular identity can have disastrous consequences. Emerging data within the field of
pancreas biology are revising current beliefs about how cellular identity is shaped by developmental and
environmental cues under homeostasis and stress conditions. Here, we discuss the changes occurring in
cellular states upon fate modulation and address how our understanding of the nature of this fluidity is
shaping therapeutic approaches to pancreatic disorders such as diabetes and cancer.Introduction
In most tissues, a mature cell performing a specialized function
represents a terminally differentiated cell that is restricted in
potential, i.e., that may possess the capacity to replicate and
expand the pool of like cells, but lacks the correct configuration
of factors to produce a different cell type. On the other side of the
spectrum, undifferentiated (or multipotent) stem cells are poised
to respond to appropriate cues and differentiate into many
different cell types. These cues include key transcription factors
that exert a pivotal influence over cell lineage trajectory, epige-
netic factors that affect the genetic framework and expression
profile of the cell, and environmental factors, such as inflam-
mation and changes in cellular metabolism that can trigger
phenotypic changes. The progression from a stem/progenitor
to a differentiated state was previously considered unidirec-
tional; however, it is now evident that fate in differentiated cells
is flexible (Cohen and Melton, 2011; Graf, 2011; Cherry and
Daley, 2012). Defining pliability of cell fate or identity, therefore,
has been a focus of regeneration research. Specifically in the
pancreas, evidence has accumulated that most terminally differ-
entiated cell types can change fate into other pancreatic cells,
supporting the notion of cellular plasticity in differentiated cells.
Gain in fate plasticity may be a strategic defense mechanism
that allows differentiated pancreatic cells to rest and avoid injury
or death caused by sustained stress. Here we evaluate emerging
data and offer insight on the connection between different
cellular states and perturbations and how the degree and type
of insult presented to a cell may be an important determinant
in whether a normally regulated defense mechanism can
become a liability.
The pancreas, derived from the endodermal lineage, is com-
posed of functionally distinct compartments that all originate
from a common pool of progenitors. Exocrine acinar cells
secrete digestive enzymes that are supplied to the gut through
an elaborate ductal tree, and endocrine cells regulate blood
glucose through secretion of hormones, including insulin and
glucagon from b and a cells, respectively. Remarkably, such18 Cell Stem Cell 16, January 8, 2015 ª2015 Elsevier Inc.diverse functional capacities emerge from a common progenitor,
prompting researchers to identify regulators of cellular identity
within the pancreas during development and the mechanisms
governing fate flexibility after differentiation is completed. Fate
plasticity in the context of pancreatic cells can be defined as
the ability of differentiated cells (exocrine and endocrine) to
lose features that define the functional, mature state of the cells
and to adopt features of other cell types within the same organ
lineage. Most likely, such changes occur in a gradual way, with
progressive loss of hallmark differentiation characteristics and
increasing ability to express genes that mark alternate cell types.
Accumulating examples that we will discuss in this Perspective
have demonstrated that mature pancreatic cells can lose their
terminally differentiated and defining functional characteristics
to become dedifferentiated. This state may be transient and
reversible; however, prolonged stress may convert such dedif-
ferentiation toward different types of pancreatic diseases as a
result of cellular transformation or functional senescence.
Understanding the triggers that encourage cellular transitions
has also uncovered events of transdifferentiation, when amature
pancreatic cell can be converted into a pancreatic cell type of
another lineage. This process may occur directly with no inter-
mediary transition stage under cases of genetic reprogramming
or forced expression of influential transcription factors or through
intermediate stages as the mature cell progressively dedifferen-
tiates to a multipotent-progenitor-like stage and then redifferen-
tiates toward another cell lineage in cases of tissue injury.
This Perspective will first discuss the genetic control of cellular
fate within the pancreas and the epigenetic regulation that
affects identity. Next, a summary of artificial manipulations that
have uncovered important roles for genetic factors in establish-
ing cellular identity will be discussed, after which will follow a dis-
cussion of the normal response of cells to distinct stressors,
such as injury. Finally, the Perspective will consider the patho-
logical consequences of changes in cellular fate in the context
of pancreatic diseases including diabetes and cancer. The
distinct changes that occur in the pancreatic cells and the
Figure 1. The Transition between Different
Cellular States in Response to Genetic
Manipulation or Injury and the Connection
to Pancreatic Disease
Schematic depicting the progressive cellular
transitions that can potentially occur in response
to insults and how these may contribute to the
manifestation of different pancreatic disorders. A
‘‘Normal’’ cell can either change cellular identity to
a novel fate, depicted as a ‘‘Transdifferentiated’’
cell, or lose functionality and become a ‘‘Dedif-
ferentiated’’ cell. Reversal from a ‘‘Dediffer-
entiated’’ state has been observed in certain
instances. Transition to a novel cellular phenotype
(‘‘Transdifferentiation’’) could occur directly or
through a dedifferentiated state. A hypothetical
‘‘Resting’’ state is also possible, wherein the cell
ceases to function normally but retains key fea-
tures of cellular identity and can presumably
reverse back to a fully functional state. Prolonged
stress, injury, or activation of oncogenic pathways
can convert a ‘‘Dedifferentiated’’ cell into a
diseased state, leading to pathogenesis. Such a
state may also be achievable if the ‘‘Trans-
differentiated’’ cell is unstable and amenable to
further fate modulation. The reversibility of a
diseased cell back to a ‘‘Normal’’ cell has great
implications for therapy and remains to be estab-
lished. Blue dashed arrows depict hypothetical
fate changes. Detailed definitions of the different
cellular states are noted.
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Table 1 and will be referred to throughout the perspective.
Flexibility of Cellular Fate Is Uncovered through
Manipulation of Developmental Programs
Cellular identities are created by sets of genetic, environmental,
and epigenetic factors that define gene expression profiles
uniquely associated with each cell fate and lineage (Huang,
2009; Cherry and Daley, 2012). Control over segregated gene
expression is largely attributed to the tightly regulated expres-
sion patterns of transcription factors (Huang, 2009). Within the
pancreas, an elegant transcriptional cascade has been identified
that exerts such control on cellular identity (Wilson et al., 2003).
During pancreatic development, a concert of transcriptional reg-
ulators leads to the specification of the exocrine (acinar and duct)
and endocrine (a, b, v, epsilon, and PP) cell types while the cell
transitions between different progenitor states (Figure 2). Many
of the same regulators continue to modulate gene expression
and cell fate in the adult organ long after differentiation states
have been established (Arda et al., 2013). Researchers have
thus turned to these factors to modulate cellular fate within the
pancreas.
Pancreatic and duodenal homeobox 1 (Pdx1) is one such
example, with a critical role in establishing cellular fate in theCell Stem Cellpancreas. It has been known for some
time that Pdx1 is required for pancreas
formation, as all compartments are de-
rived from progenitor cells that express
Pdx1 during early embryonic develop-
ment (Gu et al., 2002). The absence of
Pdx1 in both humans and mice results in
pancreatic agenesis and a failure togenerate duct, exocrine, or endocrine cell types (Jonsson
et al., 1994; Offield et al., 1996; Stoffers et al., 1997b), indicating
that Pdx1 is a master regulator for pancreas specification. A
tremendous body of work has emerged to identify the exact ac-
tivities of Pdx1 in the endocrine compartment and specifically in
the insulin-producing b cell. High Pdx1 levels are maintained in a
fully functional, mature b cell, and genetic deletion of Pdx1 in
mouse models has clearly shown a requirement of this factor
in maintenance of b cell fate and function (Ahlgren et al., 1998;
Gannon et al., 2008; Gao et al., 2014). Loss of Pdx1 translates
to a reduced capacity of the b cell to secrete insulin in response
to elevated glucose, resulting in severe hyperglycemia. In hu-
mans, mutations in PDX1 have been linked to Maturity Onset
Diabetes of the Young (MODY) (Stoffers et al., 1997a). One
way Pdx1 exerts this effect is through binding directly to the in-
sulin promoter, along with other transcriptional coactivators, to
activate insulin transcription (Iype et al., 2005). It is therefore ex-
pected that a loss of Pdx1 leads to perturbed transcription of the
insulin gene. Significantly, recent data demonstrate that Pdx1
actively represses genes that are associated with the a cell
fate, providing new insights into how this factor impacts the
maintenance of cellular identity (Gao et al., 2014). If Pdx1 is
genetically deleted in adult b cells, mice suffer from severe hy-
perglycemia due to the loss of mature properties of b cells and16, January 8, 2015 ª2015 Elsevier Inc. 19
Table 1. Examples of Cellular Fate Change within the Pancreas
Cellular Transition Modifier Mechanism of Action
Target Cell
Identity
Converted Cell
Fate Identity
Degree
of Fate
Change Setting References
Dedifferentiation pharmacological
induction of metabolic
and inflammatory injury
excessive digestive
enzyme release
acinar cell dedifferentiated
acinar cell
++ in vivo Jensen et al., 2005;
Morris et al., 2010a;
Folias et al., 2014
genetic manipulation of
transcription factors/
signaling pathways and
metabolic stress
repression of
canonical b cell
gene function
b cell dedifferentiated
b cell
++ in vivo,
in vitro
Landsman et al., 2011;
Talchai et al., 2012; Puri
et al., 2013; Guo et al.,
2013; Wang et al., 2014;
Blum et al., 2014
Transdifferentiation:
intermediary
reprogramming
cellular injury due to
pancreatic duct ligation
activation of an
embryonic gene
expression program
acinar cell multipotent
progenitor cell
+++ in vivo Pan et al., 2013
genetic manipulation of
transcription factors
transcriptional
modulation of gene
expression
b cell a cell, d cell ++++ in vivo Talchai et al., 2012; Puri
et al., 2013; Gao et al.,
2014
toxin-mediated death of
b cells, causing diabetes
transcriptional
regulation of gene
expression
a cell, d cell b cell ++++ in vivo Thorel et al., 2010; Chera
et al., 2014
Transdifferentiation:
direct
reprogramming
forced expression of key
transcription factors
transcriptional
regulation of gene
expression
acinar cell a cell, b cell,
d cell
++++ in vivo Zhou et al., 2008; Li
et al., 2014
cytokine and growth
factors
activation of STAT3
signaling
acinar cell b cell ++++ in vivo,
in vitro
Baeyens et al., 2006;
Baeyens et al., 2009;
Baeyens et al., 2014
modulation of
epigenomic elements
derepression of the
Arx promoter
through
DNA methylation
b cell a cell ++++ in vivo Dhawan et al., 2011;
Papizan et al., 2011
Resting physiological event metabolic stress b cell,
acinar cell
b cell,
acinar cell
+ in vivo predicted
Transformation oncogenic mutations in
K-ras
activation of genetic/
signaling programs
acinar cell,
duct cell
PANIN, IPMN +++++ in vivo Guerra et al., 2007; De
La O et al., 2008; Morris
et al., 2010a; Kopp et al.,
2012; von Figura et al.,
2014a
Distinct modifiers can cause conversion of adult pancreatic cells into other differentiated cell types through multiple mechanisms.
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iological signature that more closely resembles that of an a cell.
Interestingly, forced expression of Pdx1 in a cells did not convert
these cells into b cells, but rather diverted these cells into a stable
population of endocrine cells lacking any hormone expression
(Yang et al., 2011). Thus, once the a cell program has been es-
tablished, it appears that Pdx1 expression is unable to modify
it toward the b cell fate. These analyses highlight the time- and
context-dependent impact transcription factors can exert on
cellular identity.
Endocrine fate specification within the embryonic pancreatic
epithelium occurs by sequential activation and repression of
specific genes. An example of such an interaction is evident by
the inhibitory circuit of aristaless-related homeobox (Arx) and
paired box gene 4 (Pax4), which play opposing roles during
cellular differentiation. Arx promotes a cell and PP cell fates while
Pax4 is involved in b/v cell differentiation (Collombat et al., 2003,
2005). Ectopic expression in mouse models has revealed the
complex interplay of these factors in establishing cell fate.20 Cell Stem Cell 16, January 8, 2015 ª2015 Elsevier Inc.Expression of Arx in b cells led to the appearance of a cell char-
acteristics (Collombat et al., 2007), whereas forced expression of
Pax4 converted embryonic a cells into b-like cells with abnormal
physiological responses (Collombat et al., 2009). Interestingly,
deletion of Arx in a cells leads to loss of characteristics that
define the a cell and appearance of b cell markers (Courtney
et al., 2013; Wilcox et al., 2013), further supporting the notion
that transcription factors simultaneously promote desirable fates
while suppressing other fates within the same cell.
Due to the close developmental relationships shared by endo-
crine cells, many examples exist of fate conversion between the
different endocrine cell types in addition to the ones described
above. Specification of the endocrine lineage occurs through
the combined action of numerous transcription factors (Pdx1,
Nkx6.1, Nkx2.2, Sox9, Hnf6, Ngn3, Arx, Pax4, and others), and
mature cell fate is maintained by a host of factors, including
Pdx1, Nkx6.1, Pax6, Isl1, MafA, MafB, and NeuroD (Habener
et al., 2005; Benitez et al., 2012; Mansouri, 2012). Deletion of
Nkx6.1, an endocrine progenitor marker that is restricted to b
Figure 2. Acinar Dedifferentiation Is Reminiscent of Embryonic Multipotent Progenitor Cells
(A) Schematic depicting how the different pancreatic lineages arise from a common multipotent progenitor cell that is most closely related to the acinar cell.
(B) Schematic indicating points where cellular stress (resulting from injury, expression of pivotal transcription factors, metabolic pressure, or inflammation) leads
to the dedifferentiation of mature acinar cells. ADM, acinar-to-ductal metaplasia.
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statin-expressing d cells (Schaffer et al., 2013). Deletion of
Pax6, a factor important in endocrine differentiation, causes
adult islet cells to convert into ghrelin-expressing epsilon cells
that are normally absent or low in postnatal islets (Hart et al.,
2013). Concomitant deletion of Arx and Nkx2.2 perturbs fate
specification by favoring the somatostatin/ghrelin fate at the
expense of the a and b cells (Kordowich et al., 2011; Mastracci
et al., 2011). Such genetic manipulations shed light on the
requirement for several factors at various steps during fate spec-
ification and after a differentiated state is established, and they
point to the possibility of changing cell fate via approaches
that manipulate the expression of transcriptional regulators.
Similar to that of the endocrine fate regulators, the identity of
exocrine acinar cells also depends on a transcriptional cascade
including Ptf1a, Mist1, and Nr5a2, among others. Ptf1a is ex-
pressed in progenitors that give rise to acinar cells and is main-
tained in differentiated cells (Kawaguchi et al., 2002; Lin et al.,
2004; Beres et al., 2006; Holmstrom et al., 2011). The dosage
of Ptf1a may play a role in determining fate outcome, because
reduced activity of this transcription factor leads to expression
of insulin in adult acinar cells (Hesselson et al., 2011). The obser-
vation that Ptf1a expression is not conducive to endocrine
specification is suggested by an inhibitory interaction between
Ptf1a and the proendocrine factor Nkx6.1 (Schaffer et al.,2010). Overexpression of Ptf1a in pancreatic progenitors re-
presses Nkx6.1 expression and blocks endocrine differentiation.
Thus, Ptf1a both promotes acinar cell fate and suppresses the
endocrine program. Another factor important for maintenance
of acinar identify and function is Mist1 (Direnzo et al., 2012).
Mist1 knockout mice display the appearance of duct-like struc-
tures, and lineage tracing suggests that acinar cells convert to
presumptive ducts upon loss of Mist1 (Pin et al., 2001). Similarly,
Nr5a2 is also required for maintenance of acinar identity, and
loss ofNr5a2 converts acinar cells to a duct-like state (von Figura
et al., 2014b). Given the close physical relationship between
acinar and ductal cells, it might not be surprising that perturbing
the mature state of the acinar compartment leads to a conver-
sion toward the ductal fate. The ready adoption of a duct-like
fate by acinar cells is of great significance for understanding
the mechanisms underlying the development of pancreatic
ductal adenocarcinoma (PDA), and this will be discussed in
detail later. Acinar cells also demonstrate the propensity to
express markers of other lineages under specific conditions.
Deletion of c-Myc in acinar cells during embryogenesis leads
to conversion of the acinar lineage into adipocytes, as shown
by lineage tracing (Bonal et al., 2009), suggesting a role for
c-Myc in acinar differentiation.
Many attempts have beenmade to convert acinar cells into the
endocrine lineage and specifically into b cells. In a landmarkCell Stem Cell 16, January 8, 2015 ª2015 Elsevier Inc. 21
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cell program upon ectopic expression of proendocrine genes
Pdx1, MafA, and Ngn3 in acinar cells (Zhou et al., 2008). This
conversion resulted in changes to cellular gene expression, as
well as morphological and functional changes, without the pres-
ence of an observable transient intermediate serving as endo-
crine progenitor (Zhou et al., 2008). The important role of Ngn3
in suppressing exocrine fate and promoting endocrine fate was
further proposed in a follow-up study with similar in vivo experi-
ments (Li et al., 2014). Infecting acinar cells with the same three
transcription factors led to the formation of v, a, or b cells, de-
pending on the combination of factors employed. The authors
concluded that proendocrine regulators exert effects in a tempo-
ral manner that first suppress acinar fate and then establish an
endocrine state (typified by the expression of the panendocrine
gene Pax6) with subsequent induction of other endocrine genes.
As discussed above, the common theme to emerge from such
manipulations is that transcription factors serve activating and
repressive functions concomitantly.
Less is known about the transcriptional regulation that main-
tains the ductal lineage within the exocrine pancreas. The ductal
tree is composed of epithelial cells that express a distinct set of
transcriptional regulators, including Sox9, Hnf6, andHnf1b (Hau-
maitre et al., 2005; Pierreux et al., 2006; Zhang et al., 2009; Kopp
et al., 2011; Delous et al., 2012; Manfroid et al., 2012). In the
absence of a better description of themature state of ducts cells,
it is currently unclear what level of plasticity is expected from
these differentiated cells. Overexpression of Ngn3 in duct cells
isolated from human islets led to upregulated expression of
some b cell genes, but also neural genes, suggesting that
ectopic expression of Ngn3 is not sufficient for conversion of
duct cells into bona fide b cells (Kopp et al., 2011; Swales
et al., 2012). A recent paper shows that loss of a protein that par-
ticipates in the recognition motif of a ubiquitin ligase in pancre-
atic ductal cells leads to activation of the endocrine program,
as evidenced by an upregulation of Ngn3 and its downstream ef-
fectors (Sancho et al., 2014). Genetic deletion of Fbw7 leads to
the stabilization of Ngn3 (normally a short-lived protein), and
ductal cells adopt characteristics of b, a, and v cells. Further-
more, ectopic expression of a stabilized form of Ngn3 (phospho
mutant Ngn3-AA) in murine duct cells promotes transdifferentia-
tion toward the b cell phenotype with low efficiency. While Ngn3-
AA-expressing cells activate b cell markers, the response to
glucose-stimulated insulin secretion is not extensive, further
supporting the notion that factors other than Ngn3 are required
for full conversion of duct cells into b cells (Sancho et al.,
2014). The conversion frequency is low (1%), suggesting that
not all cells that are depleted of Fbw7 are equally amenable to
such redirection of fate. Nevertheless, these data implicate
Fbw7 as being critical for maintenance of ductal identity and pro-
vide another example of a regulator that is important in switching
fates within the pancreas.
Centroacinar cells lie at the interface of acinar and terminal
duct cells and have been considered candidates for pancreatic
progenitor cells (Rovira et al., 2010; Cleveland et al., 2012).
Furthermore, the gene expression profile of the centroacinar
cell is poorly characterized aside from the expression of Sox9,
a transcription factor required for endocrine specification (Sey-
mour et al., 2007), and Hes1, an effector of the Notch pathway22 Cell Stem Cell 16, January 8, 2015 ª2015 Elsevier Inc.(Kopinke et al., 2012). Despite efforts to irreversibly mark cen-
troacinar cells for lineage tracing, the contribution of this cell
type to any other lineage in vivo remains controversial (Kopinke
et al., 2011).
Epigenetic Regulation of Transcriptional Regulators
Controls Cellular Identity
While transcription factors aremost commonly involved in deter-
mining cellular identity, epigenetic regulation introduces addi-
tional layers of temporal and spatial control that can modify
genomic information. Recent evidence suggests that the histone
methylation signature of a cell can be an indicator of how easily
the cell can be coaxed toward a different lineage. Global analysis
of human islet cells revealed that many genes that are part of the
b cell signature were bivalently marked in differentiated a cells
(Bramswig et al., 2013). Such bivalency is best described in
pluripotent cells, where developmental genes are silenced and
yet poised for activation. Bivalency is conferred by concomitant
trimethylation of histone H3 lysine 4 (H3K4, considered an active
mark at the transcriptional start site and activated by the Tri-
thorax complex) and histone H3 lysine 27 (H3K27, which tran-
scriptionally represses through recruitment of the Polycomb
group of proteins). Loss of either mark can activate or repress
gene expression, allowing adoption of more than one deve-
lopmental program in response to appropriate cues (Bernstein
et al., 2006). These findings hint that the a cell may be amenable
to expressing b cell-specific genes under the appropriate condi-
tions. Treatment with a histone methyltransferase inhibitor led to
coexpression of a and b cell genes in human islet cells (Brams-
wig et al., 2013), indicating that forced epigenetic manipulation
can alter gene expression in vitro. Furthermore, transdifferentia-
tion between endocrine cells subsequent to changes in genomic
methylation has been observed in vivo. One example is through
modulation of the methylation state of the Arx locus in differenti-
ated b cells (Dhawan et al., 2011). A repressor complex that in-
cludes the homeodomain transcription factors Nkx2.2, Nkx6.1,
a corepressor Groucho-3 (Grg3), and the de novo DNA methyl-
transferase Dnmt3a is recruited to the Arx locus to prevent
expression during b cell replication (Papizan et al., 2011). Dele-
tion of the DNA methyltransferase 1 (Dnmt1), which is respon-
sible for maintaining DNAmethylation upon replication, converts
b cells into glucagon+ cells by derepressing the Arx promoter.
Thus, transcriptional regulators and epigenetic modifiers collab-
orate to suppress the expression of Arx in the b cell, and loss of
this regulation diverts b cell fate toward a cells.
Fate choice can also be modulated by acetylation and deace-
tylation of histones that in turn impacts gene expression. Both
histone acetyltransferases and histone deacetylases (HDACs)
play key roles in adoption of the appropriate pancreatic fate
from progenitors during embryonic development (Haumaitre
et al., 2008; Lenoir et al., 2011; Xu et al., 2011). Identification of
small molecules that can specifically target histone modifiers
permits us to test the role of these regulators in isolated cells.
While treatment of the glucagon-producing a cell line aTC1
with HDAC inhibitors upregulated insulin expression, treatment
of the b cell line bTC3 with these compounds led to either upre-
gulation or downregulation of genes involved in insulin secretion,
suggesting a complex regulation (Kubicek et al., 2012). Impor-
tantly, the study revealed that different classes of inhibitors could
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HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8 caused downre-
gulation of a host of b cell regulatory genes (including Pdx1,
Pax4, NeuroD, Nkx6.1, and Nkx2.2) as well as insulin, while or-
thoamino anilides, inhibiting HDAC1, HDAC2 and HDAC3, had
no effect on these genes, but caused upregulation of MafB and
Arx, resulting in increased glucagon expression in the b cell
line. Thus, specific acetyltransferases allow modulation of endo-
crine cell fates, and the identification of compounds that target
specific epigenetic pathways could be beneficial for fate modifi-
cation.
An additional layer of epigenetic control is provided by micro-
RNAs, small noncoding RNAs that silence gene expression
through sequence-specific inhibition or degradation. Pancreas
organogenesis relies on microRNA production (Lynn et al.,
2007), and several microRNAs, including miR-375, are impli-
cated in b cell function and gene expression (Poy et al., 2004,
2009; Kaspi et al., 2014) as well as exocrine tissue homeostasis
(Prevot et al., 2013). In acinar cells, microRNAs repress expres-
sion of factors that may promote adoption of ductal fates (Prevot
et al., 2013). Similarly, microRNAs in the b cell regulate expres-
sion of genes such as Mct1, which inhibits glucose-stimulated
insulin secretion (Pullen et al., 2011). Further work will delineate
how repression of undesirable fates by microRNAs contributes
tomaintenance of cellular identity and howmanipulation of these
small RNAs can allow cellular adoption of alternative fates.
Resting versus Dedifferentiated Cells: When Is
Dedifferentiation Part of the Normal Cellular
Phenotype?
The previous notion of terminal differentiation as a fixed state has
been revised due to substantial evidence on the alterations in
fullymatured cells in response to certain stresses.Most attempts
at changing cell fate involve overriding the regulatory mecha-
nisms that are normally in place to control cell identity through
artificial means. Thus, the following question arises: can this
inherent plasticity be part of a cell’s normal response to stress,
or is it only identifiable under conditions of artificial genomic or
epigenomic manipulation? Is there a narrow range of fate modi-
fication that a cell can tolerate as part of the normal physiological
response? Are there distinct points of no return during changes
in cellular differentiation, after which a switch back to the previ-
ous state becomes impossible?Muchwork lies ahead in order to
fully uncover what buffering mechanisms are in place to allow a
cell to maintain identity. Although increasing evidence suggests
that cells do respond to challenges by transitioning to novel phe-
notypes, it remains to be determined whether the new differenti-
ation state is equivalent to a cell that is formed during normal
organogenesis or if it represents a new cell type.
A common cellular response to specific injuries or manipula-
tions is the stimulation of cellular dedifferentiation (Figure 1).
Currently, dedifferentiation is defined as a loss of the hallmark
characteristic state that identifies a terminally differentiated
cell. Cells may lose their normal mature state and become pliable
to fate change, either inherently or through external stimulation.
Alternatively, cells may dedifferentiate and cease to function but
persist in an undefined or resting state while the insult persists. In
the first instance, dedifferentiation is a transition step before the
adoption of a novel identity, characterized by reemergence offactors that promote redirection of fate. In the second case,
dedifferentiation could be viewed as an adaptive response to a
stressful stimulus, such that the cell ceases normal activity to
prohibit progression toward cellular dysfunction, culminating,
in extreme cases, in cell death. This phenomenonmay be viewed
as a transient ‘‘resting’’ state for a cell to regroup and allow the
insult to subside. Examples of both of these scenarios are sug-
gested within the pancreas.
A substantial amount of evidence has demonstrated the ease
with which pancreatic acinar cells dedifferentiate into cells
resembling a duct-like phenotype in response to stresses such
as injury or inflammation. Acinar cells undergo morphological
changes, with a reduction in the expression of mature acinar
markers concomitant with increased expression of factors nor-
mally expressed during embryonic development. Because the
dedifferentiated cells exhibit qualities reminiscent of both a
duct cell and a progenitor cell present during pancreatic devel-
opment (including the expression of Sox9, Hnf6, Hes1, Pdx1,
and Nestin), the term duct-like cell has been used to describe
this population (Song et al., 1999; Jacquemin et al., 2003; Miya-
moto et al., 2003; Jensen et al., 2005; Seymour et al., 2008; Mor-
ris et al., 2010a; Shi et al., 2013). The duct-like cells are not true
progenitors, however, because they lack expression of other
markers, including Hnf1b and Nkx6.1 (Jensen et al., 2005; Solar
et al., 2009; Schaffer et al., 2010; Pre´vot et al., 2012).
A common notion is that acinar dedifferentiation may create a
facultative progenitor cell capable of repopulating different types
of pancreatic cells. During early development of the pancreas,
multipotent progenitor cells residing at the tips of epithelial
branches divide and leave behind progeny that differentiate
into duct and endocrine cells that form the trunk of the branches
(Figure 2A). The multipotent progenitors at the tips will eventually
differentiate into acinar cells, suggesting that acinar cells are the
most direct progeny of embryonic multipotent progenitor cells
(Figure 2A) (Zhou et al., 2007; Solar et al., 2009). While contro-
versy exists over whether an adult pancreatic stem cell exists,
dedifferentiation of acinar cells into multipotent progenitor cells
offers an attractive model for cell replacement in the adult pan-
creas. Indeed, acinar to duct-like dedifferentiation is observed
under different models of pancreatic injury, including partial
duct ligation (PDL) and chemically induced pancreatitis, perhaps
suggestive of pancreatic cells adopting a more progenitor-like
state that can help repopulate the organ after injury. For ex-
ample, when the cholecystokinin (CCK) analog caerulein is
used to pharmacologically stimulate acinar cells to secrete
continuous and excessive amounts of digestive enzymes, acinar
cells respond by shutting down expression of digestive enzymes
and initiating expression of progenitor/stress factors (Jensen
et al., 2005; Siveke et al., 2008; Morris et al., 2010a). The extent
and degree of dedifferentiation is dependent upon the duration
of injury, suggesting that this is a protective response that re-
duces the harmful effects of digestive enzymes on acinar cells
and simultaneously generates a cell with progenitor-like qualities
to repopulate the damaged pancreas. Notably, regeneration de-
pends on interaction with immune cells that serve as critical reg-
ulators of acinar cell redifferentiation (Folias et al., 2014).
In another study of severe injury to the exocrine compartment,
cells expressing endocrine progenitor markers localized to the
ductal lining, suggesting that either a new progenitor cell isCell Stem Cell 16, January 8, 2015 ª2015 Elsevier Inc. 23
Figure 3. Endocrine Fate Conversion within
the Islet
Fate change between endocrine cells is observed
under different conditions of stress. This may
occur either directly or through a dedifferentiated
state. Continued stress on the b cell can lead to
dedifferentiation that causes diabetes.
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may be enhanced in situations of intense pressure (Xu et al.,
2008). Reprogramming of the ductal lineage to an endocrine
fate has been controversial, because lineage tracing demon-
strates that although Ngn3 is induced in duct cells upon PDL,
the levels are insufficient to induce endocrine and b cell forma-
tion (Kopp et al., 2011). Ngn3 is an unstable protein, and one
possibility for the failure of ductal cellular reprogramming could
be rapid degradation of Ngn3. As noted above, Fbw7 was
dramatically reduced upon induction of pancreatic injury, such
as PDL, which might suggest that the extent of the damage
(whichwould correlate with the reduction in Fbw7 and the conse-
quent stabilization of Ngn3) may determine the ability of cells to
undergo fate change (Sancho et al., 2014). A recent study
wherein acinar cells were transiently labeled in adult mice prior
to injury by PDL demonstrated that while most acinar cells
died, some cells located at the tips acquired themolecular signa-
ture of embryonic multipotent progenitor cells present at the end
of pancreatic branches (Pan et al., 2013). Multipotency was
confirmed in these progenitors when they gave rise to exocrine
acinar and duct cells, as well as cells of the endocrine pancreas
(Figure 2B). This study supports the idea that adult acinar cells
retain the potential to revert into progenitor-like cells with self-
renewal and multipotent capacities. What remains unclear is
whether all acinar cells have this capacity or whether the niche
environment of the cell might limit or create increased multipo-
tentiality. It is also important to consider the type of insult,
because different models of injury provide divergent outcomes
(Desai et al., 2007).
Dedifferentiation in the context of a diseased state has been
observed in the endocrine compartment as well, although the
physiological stressors are distinct from those in the exocrine
system. In the presence of metabolic stress due to persistent hy-
perglycemia and insulin resistance, b cells are forced to function
at supranormal levels. Such glucotoxicity leads to loss of cellular
function and cell death (Butler et al., 2003; Poitout and Robert-
son 2008). However, different types of stresses, either genetic
or metabolic, have all converged on a new look at dedifferentia-
tion in the b cell as a potential cause for disease, and dedifferen-
tiation has been recently introduced as an alternative fate to cell24 Cell Stem Cell 16, January 8, 2015 ª2015 Elsevier Inc.death in the context of type II diabetes
(Figure 3). For example, b cell-specific
deletion of the transcription factor Foxo1
during states of metabolic stress (in-
cluding aging and pregnancy) results in
reduced b cell mass that causes diabetes
(Talchai et al., 2012). Intriguingly, lineage-
tracing studies showed that b cells do not
undergo apoptosis but dedifferentiate
into cells that have lost the canonical bcell marker expression. These dedifferentiated b cells appeared
to express stem cell markers, including Oct4, and could occa-
sionally redifferentiate into other hormone-producing cell types
(Talchai et al., 2012). Similar findings were reported in a mouse
model of b cell inexcitability, wherein ectopic expression of a
gain-of-function mutation in the KATP channel led to dedifferen-
tiation in b cells (Wang et al., 2014). In both studies, progenitor
markers, defined as genes normally absent from mature b cells
but present in pancreas progenitors, were observed in the dedif-
ferentiated b cells, while adoption of non-b cell fates by the de-
differentiated cells was not observed upon sustained activation
of the KATP channel. Thus, depending on the exact nature of
the stressor, distinct outcomes are reached. The onset of dedif-
ferentiation also had significantly different temporal require-
ments in each study. In the Talchai et al. study, diabetes onset
was well into adulthood, and it presented with a progressive
deterioration of b cell function, reminiscent of how the disease
develops in humans. The dedifferentiation seen in the activated
KATP context occurs rapidly, in that hyperglycemia is observed
within 20 days after administration of tamoxifen. Thus, different
perturbations may impact the timing and extent of b cell dediffer-
entiation. Similarly, oxidative stress modifies the cellular state,
causing reduced activity of important transcription factors as a
result of displacement from the nucleus (Guo et al., 2013).
PDX1 and a small subset of key islet-enriched transcription
factors were reduced in b cells from islets isolated from type II
diabetic patients (Guo et al., 2013) and in rodents with chronic
hyperglycemia (Harmon et al., 1999; Jonas et al., 1999). Interest-
ingly, progenitor factors (NEUROGENIN 3, NANOG, POU5F1,
and MYCL1) found in previous rodent studies were not detected
in islets from humans with type II diabetes, suggesting that there
may be species-specific differences in the stress response of is-
lets (Guo et al., 2013). This study underscores the importance of
subcellular localization of transcription factors, because gene
expression levels would be less informative in such a scenario.
Inappropriate activation of the embryonic Hedgehog signaling
pathway in adult b cells also induces dedifferentiation and
compromised cellular function, including reactivation of the pro-
genitor markers Hes1 and Sox9 (Landsman et al., 2011). While
transdifferentiation into other pancreatic cell types was not
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transgene responsible for sustained Hedgehog signaling activity
allowed cells to redifferentiate into functional b cells (Landsman
et al., 2011). These findings support the notion of reversibility of a
dedifferentiated state upon cessation of the original stressor.
Lastly, alterations in the metabolic state of the cell can cause
modifications in cellular identity. This is evident upon erroneous
activation of the hypoxia response pathway that leads to b cell
dedifferentiation, with concomitant activation of a subset of em-
bryonicmarkers (Puri et al., 2013). In themajority of the studies, b
cells appeared to persist in a dedifferentiated state, with only a
fraction of the dedifferentiated cells demonstrating the ability
to adopt alternative fates. Such prolonged dedifferentiation
may be viewed as a mechanism that allows the cell to reduce
the need to continuously produce insulin and thus achieve a
resting state that at least temporarily might stave off cell death
signaling. Evidence that such a state is reversible comes from
the observation that introduction of exogenous insulin lowered
the physiological hyperglycemia in KATP mutant animals and
appeared to reverse the b cell dedifferentiation phenotype
(Wang et al., 2014). A pressing question is whether such rediffer-
entiation occurs under other stress conditions as well. It is likely
that the extent of b cell dedifferentiation will determine how
reversible this condition would be. In other words, impaired b
cell functionality that might be observed during the early stages
of human prediabetes or diabetes might be reversible if the un-
derlying stressor that causes b cell dedifferentiation is removed.
A detailed understanding of this process is an avenue worth pur-
suing, as it could have significant implications toward our under-
standing of the development and management of diabetes.
Collectively, manipulations within both the endocrine and
exocrine compartments suggest that distinct pressures cause
cells to first transition into a ‘‘resting’’ state (Figure 1), with down-
regulation of factors that are creating stress, such as those pro-
moting production of digestive enzymes in the acinar cell and
insulin in the b cell. This initial decrease in expression of factors
critical to the overall function of the cell may represent a transition
period that occurs before dedifferentiation, wherein cells maintain
normal cellular morphology and defining characteristics. If the
pressure is too great or persistent enough, this resting state pro-
gresses further to an overt dedifferentiated state wherein the cell
undergoes more dramatic changes in the expression of defining
factors, as well as changes in morphological and functional fea-
tures (Figure 1 and Figure 2B). It is reasonable to consider that
both the resting and dedifferentiated states of a cell are transient
and that the cell can be restored to normal if the pressures are
relieved in time (Landsman et al., 2011). While reversibility of
fate in dedifferentiated b cells is still a new concept, this idea is
clearly evident in models wherein pancreatic acinar cells are
able to regenerate after dedifferentiation in response to caerulein
treatment (Jensen et al., 2005). However, it is important to
consider that persistent and/or intense pressure can cause
erosion of normal phenotypic and functional characteristics to a
pointwhere the cell undergoes permanent changes in cellular fate.
Is Dedifferentiation a Gateway for Transdifferentiation?
An interesting phenomenon in progressive dedifferentiation is
the process of transdifferentiation (Figure 1). We define transdif-
ferentiation or cellular reprogramming as the conversion of onespecialized cell into a different cell lineage (Figure 1). Different
methods, both naturally occurring and experimental manipula-
tions, have resulted in the transdifferentiation of pancreatic cells
in both the endocrine and exocrine compartments. This process
of cellular reprogramming might occur via distinct routes (Fig-
ure 1). For example, intermediary transdifferentiation requires
that a mature cell first dedifferentiate into a progenitor cell that
can then give rise to a cell of a different origin (Transdifferentia-
tion 1, Figure 1). A second scenario that is documented in the
field is the conversion of cell fates without an observable or
detectable intermediate step; this is termed direct reprogram-
ming (or Transdifferentiation 2, Figure 1).
An example of intermediary transdifferentiation can be seen
when acinar cells dedifferentiate into a duct-like cell with
exocrine and endocrine potential. So far, evidence suggests
that pancreatic cells only give rise to other pancreatic lineages
and not other tissues or germ layers. Even though the appear-
ance of stem cell markers Oct4 and Nanog has been reported
in dedifferentiated b cells (Talchai et al., 2012), there is no evi-
dence that these cells can give rise to nonendocrine lineages
despite the expression of pluripotency markers. It is conceivable
that a dedifferentiated cell might retrace the normal develop-
mental path toward a different, albeit closely related, cell type
once it has reached the progenitor state.
Direct reprogramming of the exocrine pancreas into an
endocrine population using exogenous factors demonstrates
that cells can be prompted to directly transdifferentiate (Zhou
et al., 2008; Li et al., 2014). Recent reports further demonstrated
both in vitro (Baeyens et al., 2005, 2006, 2009) and in vivo
(Baeyens et al., 2014) that acinar cells can be reprogrammed
into b-like cells in response to cytokine treatment with
epidermal growth factor (EGF) and ciliary neurotrophic factor
(CNTF). Notably, treatment with EGF and CNTF led to reprog-
ramming of acinar cells in hyperglycemic diabetic mice by
generating a functional b cell mass sufficient to restore and
maintain normoglycemia in an indirect process dependent on
Ngn3 and signaling through Stat3 (Baeyens et al., 2014). The
authors do not report a dedifferentiation step in the process of
converting the acinar cells into endocrine progenitors, furthering
the notion that acinar cells directly (without transitioning through
a dedifferentiation state) switch fate into the b cell lineage. While
these studies provide evidence that cells originating from the
acinar lineage can be reprogrammed into b cells capable of
regulating glycemia to a certain extent, it remains unclear
whether acinar-derived cells achieve a state identical to that
of normal islet b cells.
As previously discussed, the endocrine pancreas also ap-
pears to have a significant ability to switch fates between
different islet cell types. Ablation of b cells prompted the adja-
cent glucagon-expressing a cells and somatostatin-expressing
v cells to spontaneously acquire features of insulin-producing b
cells (Thorel et al., 2010; Chera et al., 2014). Furthermore, con-
version of b cells into a like cells after loss of Pdx1 showed no
evidence for an endocrine progenitor state (described as the
lack of expression of Arx or Ngn3), suggesting a direct conver-
sion through a hybrid state in which cells display properties of
both a and b cells (Gao et al., 2014). Reaggregation of dispersed
human islets led to spontaneous conversion of b cells into a cells
in an Arx-dependent manner, although the glucagon-expressingCell Stem Cell 16, January 8, 2015 ª2015 Elsevier Inc. 25
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This cell may resemble the multihormone-positive cell that can
be generated from human embryonic stem cells during directed
differentiation, wherein inappropriate cues can lead to simulta-
neous activation of b cell and a cell-specific genes (Rezania
et al., 2011). Conversion of b cells into other endocrine cells sub-
sequent to dedifferentiation has also been demonstrated (Tal-
chai et al., 2012; Puri et al., 2013). Such fate conversion between
endocrine cells is likely facilitated by the substantial similarity in
genome-wide chromatin structure between the different endo-
crine cells. Thus, suppression of b cell identity might eliminate
factors that normally repress non-b endocrine cell identities.
Overall the idea that the identity of endocrine cells is fragile
and can be disrupted in cases of metabolic stress has led to
the theory that b cell dedifferentiation, rather than b cell death,
is an underappreciated cause of b cell failure in diabetes (in
type II and possibly type I diabetes). If this is the case, reversal
of this process might be achievable by pushing dedifferentiated
b cells or transdifferentiated endocrine cells back to their original
functional mature state (Landsman et al., 2011).
Importantly, full transdifferentiation is currently difficult to
establish because we are still trying to establish parameters to
evaluate the extent of conversion. In general, it is not clear
whether morphology, gene expression, epigenetic landscape,
ultrastructure, or function of a transdifferentiated cell are iden-
tical to that of a cell formed during normal development. The
most critical factors that need to be resolved to fully evaluate
transdifferentiated cells are the extent of their maturity and the
stability of the newly acquired characteristics. While examples
clearly exist that describe direct reprogramming without the
requirement of an intermediate transition stage, future work will
help resolve how these changes in cellular phenotypes differ
from those of intermediary reprogramming or development.
Hijacking Flexibility for Irreversibility: The Path
to Cancer
Pathological conditions that encourage fluidity in cellular plas-
ticity and the reemergence of progenitor factors in both the
endocrine and exocrine compartment can also render these
cells susceptible to oncogenic transformation. In the absence
of tumorigenic pressures, it is believed that partially differenti-
ated cells prefer to revert back toward a more stable state of ter-
minal differentiation. In the case of cellular transformation
involving active oncogenes, the continuous change suggests
that neoplastic cells have lost fate constraints and can adopt
a permanently dedifferentiated state that promotes cancer
formation.
A clear example of such plasticity being misdirected toward
disease is in the etiology of pancreatic adenocarcinoma (PDA).
Current data support the notion that PDA can arise from distinct
neoplastic lesions, including pancreatic intraepithelial neoplasia
(PanIN), mucinous cystic neoplasm (MCN), and intraductal papil-
lary mucinous neoplasia (IPMN) (Feldmann et al., 2007; Matthaei
et al., 2011). Determining the cellular source of PDA has been
challenging in humans because the histological appearances
and morphological features used to classify neoplasia and tu-
mors do not necessarily predict the cell of origin. Nevertheless,
an impressive body of research using animal models has been
devoted to identifying mutations and characterizing the precur-26 Cell Stem Cell 16, January 8, 2015 ª2015 Elsevier Inc.sor lesions that lead to formation of PDA within the pancreas.
Recent evidence points to both acinar and duct cells as potential
sources of precancerous lesions (Carrie`re et al., 2007; Guerra
et al., 2007; De La O et al., 2008; Habbe et al., 2008; Morris
et al., 2010a; Kopp et al., 2012; Pylayeva-Gupta et al., 2012;
Shi and Hruban 2012; von Figura et al., 2014a). Acinar cells un-
dergo dedifferentiation into a duct-like state under certain types
of injury, as described previously. Activated Kras (KrasG12D) has
the ability to hijack the dedifferentiated cellular state to initiate
formation of PanIN lesions in mouse models (Morris et al.,
2010b; Kopp et al., 2012). Lineage tracing studies have demon-
strated that KrasG12D can induce PanIN formation by destabiliz-
ing the acinar cell phenotype and initiating the transition of acinar
cells into a duct-like state, an important event in tumor progres-
sion (Habbe et al., 2008; Kopp et al., 2012). Furthermore, the
ductal factor Sox9 synergizes with Kras to accelerate acinar re-
programming, indicating that progression through a duct-like
state may be a critical determinant of Kras-induced PanIN for-
mation (Kopp et al., 2012).
Duct cells have also been suggested as a cellular source of
origin for PDA. Specific deletion of the epigenetic regulator
Brg1, an essential member of SWI/SNF complexes, renders
duct cells sensitive to oncogenic Kras-driven neoplastic trans-
formation, supporting the idea that duct cells can contribute to
the formation of IPMN lesions (von Figura et al., 2014a). It re-
mains unclear whether duct cells undergo a similar dedifferenti-
ation step observed in acinar cells during or prior to Kras-driven
transformation. It is also unknown whether dedifferentiation of
both mature acinar cells and mature ductal cells can result in a
similar dedifferentiated duct-like progenitor cell in both cases.
Hypothetically, dedifferentiation of both cell types might lead
to the formation of a similar intermediate progenitor cell, with
the context-dependent genetic and environmental factors
shaping the aggressiveness and nature of PDA development.
Alternatively, acinar and duct-derived cancers retain information
regarding their origin, suggesting profound differences despite
similar morphology of the respective tumors. Independent of
the cell of origin, factors like inflammation and metabolic stress,
accompanied by a genetic predisposition, can catapult a dedif-
ferentiated cell into a disease-causing trajectory that leads to
transformation and changes in both cellular identity and behavior
(Figure 1). Thus, in the presence of oncogenic mutations, fate
plasticity proves to be detrimental.
Cancers of the endocrine pancreas called pancreatic neu-
roendocrine tumors (pNETs) can occur that contain either
nonfunctional endocrine cells (maintaining an apparent endo-
crine cell identity, but not secreting any identifiable hormone)
or functioning endocrine cells (cells that can secrete normal
islet hormones, hormones characteristic of the fetal pancreas,
or factors produced by islet cells at any stage of development)
(Klo¨ppel, 2011). Islet dedifferentiation and the acquisition of a
different endocrine-like identity may also be the driving force
that propels genetically predisposed cells into an oncogenic
transformation. Currently the cell of origin of pNET in humans
remains unknown. Manipulation of tumor suppressor genes in
b and a cells induces insulinomas and glucagonomas, support-
ing the tumorigenic potential of these cells and an endocrine
origin of pNET (Bertolino et al., 2003; Lu et al., 2010). However,
it has also been suggested that pNET might actually arise from
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crine potential from acinar cells support this idea, but whether
this actually occurs in humans remains a mystery (Kamisawa
et al., 2002; Vortmeyer et al., 2004). Summarily, it appears
that risk factors such as chronic pancreatitis or genetic variants
that render pancreatic cells more plastic may reduce the
threshold for pancreatic dedifferentiation and increase the like-
lihood of the development of different types of pancreatic
cancers.
Clinical Implications: How Are Therapeutic Strategies
Changing?
Understanding that pancreatic cells are more fluid than pre-
viously expected and that the changes in cellular plasticity
contribute to the manifestation of different pancreatic diseases
promises a tremendous impact on therapeutic approaches.
Importantly, identifying factors that promote, inhibit, or stabilize
this process could have valuable implications for different treat-
ment strategies for b cell replacement therapy, diabetes, and
pancreatic cancer. In the mouse model of pancreatic cancer,
removal of oncogenic Kras activity in established precursor le-
sions can revert the cells back to an acinar fate and reduce tu-
mor burden (Collins et al., 2012; Ying et al., 2012), pointing to a
need for the development of Kras inhibitors. If changes in cell
fate are as reversible as they are readily created, then new ther-
apeutics can target factors that inhibit dedifferentiation or pro-
mote redifferentiation depending on the physiological situation.
Accomplishing this in a functional and controlled manner re-
quires the detailed and progressive analysis of different cellular
states during degenerative diseases, as well as the identifica-
tion of biomarkers that can differentiate these distinct transition
states.
The notion that cellular fates of both mature and immature
cells can easily be altered bymanipulation of specific factors em-
phasizes the need for us to identify the critical regulators that
exert a pivotal influence over the differentiation fate of individual
pancreatic cells. Such information is directly applicable to cur-
rent b cell replacement strategies that are aimed at generating
b cells for transplantation purposes from the differentiation of
alternative cellular sources such as human embryonic stem cells.
Identification of regulators that can modify, maintain, or erode
cellular fate can lead to the application of such information to
optimizing differentiation protocols that are geared toward
generating vast quantities of b cells for replacement therapy.
Additionally, different approaches in regenerative medicine
designed to promote the transdifferentiation of pancreatic cell
types into b cells are also dependent upon manipulating the
expression of influential transcription factors or modifying the
epigenetic landscape of cells to promote changes in cellular
fate. Lastly, understanding how different factors can alter cellular
differentiation increases our ability to perform sophisticated, and
easily manipulated, disease modeling in human in vitro systems
(Shang et al., 2014). These new ideas in cellular plasticity expand
our ability to manipulate patient-specific cells that have gene
mutations already identified. These cells can be used as a
screening platform for drug discovery and for the exploration
of how mutations affect the function of individual cells removed
from a complex physiological system, and they can provide
in vitro systems wherein human mutations can be correctedand investigated. Overall, it is becoming clear that understanding
cellular plasticity and differentiation offers applicable therapeutic
potential to pancreatic tissue injury and regeneration, diabetes,
and pancreatic cancer.
Conclusion
Our understanding of the impact of cellular plasticity on tissue
function and disease formation continues to evolve. Manipula-
tions within embryonic progenitors during pancreas organogen-
esis have informed us of the critical players that regulate cellular
identity. Applying such findings to mature, fully differentiated
cells has revealed that pancreatic cells exhibit more fluidity in
cellular fate than previously thought. Examples of such fate
flexibility have also been noted in other tissues. For instance,
dedifferentiation in response to injury in nerve cells promotes
regeneration through replication, and transdifferentiation of B
cells into macrophages can be induced by forced expression
of key transcription factors (Jopling et al., 2011). In response to
genetic factors, epigenetic factors, and environmental cues,
cells can be prompted to transition through different stages.
The propensity and extent of these cellular transitions is depen-
dent upon the severity of exposure and receptivity of the cell to
these stimuli. Naturally occurring pressures such as injury or
metabolic or inflammatory stress can induce a more pliable
cellular state (either a resting state or a dedifferentiated state)
that can be transient or prolonged depending on the duration
of the insult. A cell’s adoption of a resting or dedifferentiated
state can temporarily allow a suspension of the normal cellular
functions as a preventive measure to circumvent injury or death.
This idea is exemplified by the fragility of endocrine cells that can
undergo dedifferentiation rather than apoptosis in cases of
persistent metabolic stress (Talchai et al., 2012; Guo et al.,
2013; Puri et al., 2013). Alternatively, dedifferentiation in
response to stressmay cause the emergence of cellular flexibility
that permits a cell’s transformation into a different cellular fate.
This may lead the cell to undergo intermediary transdifferentia-
tion, progressively converting into another terminally differenti-
ated cell. Finally, pathological conditions that encourage fate
fluidity and the reemergence of progenitor factors can also
render pancreatic cells susceptible to oncogenic transformation.
Identifying ways to harvest or inhibit this flexibility in a directed
effort can improve different approaches in the prevention and
treatment of pancreatic diseases. The idea that terminally differ-
entiated cells retain an inherent plasticity substantially increases
the opportunities of targets that can be used to restore tissue
function in cases of disease and destruction.
AUTHOR CONTRIBUTIONS
S.P., A.E.F., and M.H. conceived the general topics of the Perspective and
cowrote the manuscript.
ACKNOWLEDGMENTS
We thank Drs. Audrey Parent, Nilotpal Roy, and Holger A. Russ for critically
reading the manuscript. We thank The Leona M. and Harry B. Helmsley
Charitable Trust (09PG-T1D018), the Juvenile Diabetes Research Founda-
tion (JDRF 17-2013-380), and the NIH and NCI (R01CA172045) for sup-
porting the work in the laboratory of M.H. and the Juvenile Diabetes
Research Foundation (3-2011-95) for supporting the postdoctoral fellow-
ship of A.E.F.Cell Stem Cell 16, January 8, 2015 ª2015 Elsevier Inc. 27
Cell Stem Cell
PerspectiveREFERENCES
Ahlgren, U., Jonsson, J., Jonsson, L., Simu, K., and Edlund, H. (1998). beta-
cell-specific inactivation of the mouse Ipf1/Pdx1 gene results in loss of the
beta-cell phenotype and maturity onset diabetes. Genes Dev. 12, 1763–1768.
Arda, H.E., Benitez, C.M., and Kim, S.K. (2013). Gene regulatory networks
governing pancreas development. Dev. Cell 25, 5–13.
Baeyens, L., De Breuck, S., Lardon, J., Mfopou, J.K., Rooman, I., and Bou-
wens, L. (2005). In vitro generation of insulin-producing beta cells from adult
exocrine pancreatic cells. Diabetologia 48, 49–57.
Baeyens, L., Bonne´, S., German, M.S., Ravassard, P., Heimberg, H., and Bou-
wens, L. (2006). Ngn3 expression during postnatal in vitro beta cell neogenesis
induced by the JAK/STAT pathway. Cell Death Differ. 13, 1892–1899.
Baeyens, L., Bonne, S., Bos, T., Rooman, I., Peleman, C., Lahoutte, T.,
German, M., Heimberg, H., and Bouwens, L. (2009). Notch signaling as gate-
keeper of rat acinar-to-beta-cell conversion in vitro. Gastroenterology 136,
1750–1760, e1713.
Baeyens, L., Lemper, M., Leuckx, G., De Groef, S., Bonfanti, P., Stange´, G.,
Shemer, R., Nord, C., Scheel, D.W., Pan, F.C., et al. (2014). Transient cytokine
treatment induces acinar cell reprogramming and regenerates functional beta
cell mass in diabetic mice. Nat. Biotechnol. 32, 76–83.
Benitez, C.M., Goodyer, W.R., and Kim, S.K. (2012). Deconstructing pancreas
developmental biology. Cold Spring Harb. Perspect. Biol. 4, http://dx.doi.org/
10.1101/cshperspect.a012401.
Beres, T.M., Masui, T., Swift, G.H., Shi, L., Henke, R.M., and MacDonald, R.J.
(2006). PTF1 is an organ-specific and Notch-independent basic helix-loop-he-
lix complex containing the mammalian Suppressor of Hairless (RBP-J) or its
paralogue, RBP-L. Mol. Cell. Biol. 26, 117–130.
Bernstein, B.E., Mikkelsen, T.S., Xie, X., Kamal, M., Huebert, D.J., Cuff, J., Fry,
B., Meissner, A., Wernig, M., Plath, K., et al. (2006). A bivalent chromatin struc-
ture marks key developmental genes in embryonic stem cells. Cell 125,
315–326.
Bertolino, P., Tong, W.M., Herrera, P.L., Casse, H., Zhang, C.X., and Wang,
Z.Q. (2003). Pancreatic beta-cell-specific ablation of the multiple endocrine
neoplasia type 1 (MEN1) gene causes full penetrance of insulinoma develop-
ment in mice. Cancer Res. 63, 4836–4841.
Blum, B., Roose, A.N., Barrandon, O., Maehr, R., Arvanites, A.C., Davidow,
L.S., Davis, J.C., Peterson, Q.P., Rubin, L.L., andMelton, D.A. (2014). Reversal
of beta cell de-differentiation by a small molecule inhibitor of the TGFbeta
pathway. eLife 3, http://dx.doi.org/10.7554/eLife.02809.
Bonal, C., Thorel, F., Ait-Lounis, A., Reith, W., Trumpp, A., and Herrera, P.L.
(2009). Pancreatic inactivation of c-Myc decreases acinar mass and transdif-
ferentiates acinar cells into adipocytes in mice. Gastroenterology 136,
309–319, e309.
Bramswig, N.C., Everett, L.J., Schug, J., Dorrell, C., Liu, C., Luo, Y., Streeter,
P.R., Naji, A., Grompe, M., and Kaestner, K.H. (2013). Epigenomic plasticity
enables human pancreatic a to b cell reprogramming. J. Clin. Invest. 123,
1275–1284.
Butler, A.E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R.A., and Butler,
P.C. (2003). Beta-cell deficit and increased beta-cell apoptosis in humans
with type 2 diabetes. Diabetes 52, 102–110.
Carrie`re, C., Seeley, E.S., Goetze, T., Longnecker, D.S., and Korc, M. (2007).
The Nestin progenitor lineage is the compartment of origin for pancreatic intra-
epithelial neoplasia. Proc. Natl. Acad. Sci. USA 104, 4437–4442.
Chera, S., Baronnier, D., Ghila, L., Cigliola, V., Jensen, J.N., Gu, G., Furuyama,
K., Thorel, F., Gribble, F.M., Reimann, F., and Herrera, P.L. (2014). Diabetes re-
covery by age-dependent conversion of pancreatic d-cells into insulin pro-
ducers. Nature 514, 503–507.
Cherry, A.B., and Daley, G.Q. (2012). Reprogramming cellular identity for
regenerative medicine. Cell 148, 1110–1122.
Cleveland, M.H., Sawyer, J.M., Afelik, S., Jensen, J., and Leach, S.D. (2012).
Exocrine ontogenies: on the development of pancreatic acinar, ductal and
centroacinar cells. Semin. Cell Dev. Biol. 23, 711–719.28 Cell Stem Cell 16, January 8, 2015 ª2015 Elsevier Inc.Cohen, D.E., and Melton, D. (2011). Turning straw into gold: directing cell fate
for regenerative medicine. Nat. Rev. Genet. 12, 243–252.
Collins, M.A., Bednar, F., Zhang, Y., Brisset, J.C., Galba´n, S., Galba´n, C.J.,
Rakshit, S., Flannagan, K.S., Adsay, N.V., and Pasca di Magliano, M. (2012).
Oncogenic Kras is required for both the initiation and maintenance of pancre-
atic cancer in mice. J. Clin. Invest. 122, 639–653.
Collombat, P., Mansouri, A., Hecksher-Sorensen, J., Serup, P., Krull, J., Grad-
wohl, G., and Gruss, P. (2003). Opposing actions of Arx and Pax4 in endocrine
pancreas development. Genes Dev. 17, 2591–2603.
Collombat, P., Hecksher-Sørensen, J., Broccoli, V., Krull, J., Ponte, I., Mun-
diger, T., Smith, J., Gruss, P., Serup, P., and Mansouri, A. (2005). The simulta-
neous loss of Arx and Pax4 genes promotes a somatostatin-producing cell
fate specification at the expense of the alpha- and beta-cell lineages in the
mouse endocrine pancreas. Development 132, 2969–2980.
Collombat, P., Hecksher-Sørensen, J., Krull, J., Berger, J., Riedel, D., Herrera,
P.L., Serup, P., and Mansouri, A. (2007). Embryonic endocrine pancreas and
mature beta cells acquire alpha and PP cell phenotypes upon Arx misexpres-
sion. J. Clin. Invest. 117, 961–970.
Collombat, P., Xu, X., Ravassard, P., Sosa-Pineda, B., Dussaud, S., Billestrup,
N., Madsen, O.D., Serup, P., Heimberg, H., and Mansouri, A. (2009). The
ectopic expression of Pax4 in the mouse pancreas converts progenitor cells
into alpha and subsequently beta cells. Cell 138, 449–462.
Courtney, M., Gjernes, E., Druelle, N., Ravaud, C., Vieira, A., Ben-Othman, N.,
Pfeifer, A., Avolio, F., Leuckx, G., Lacas-Gervais, S., et al. (2013). The inactiva-
tion of Arx in pancreatic a-cells triggers their neogenesis and conversion into
functional b-like cells. PLoS Genet. 9, e1003934.
De La O, J.P., Emerson, L.L., Goodman, J.L., Froebe, S.C., Illum, B.E., Curtis,
A.B., and Murtaugh, L.C. (2008). Notch and Kras reprogram pancreatic acinar
cells to ductal intraepithelial neoplasia. Proc. Natl. Acad. Sci. USA 105, 18907–
18912.
Delous, M., Yin, C., Shin, D., Ninov, N., Debrito Carten, J., Pan, L., Ma, T.P.,
Farber, S.A., Moens, C.B., and Stainier, D.Y. (2012). Sox9b is a key regulator
of pancreaticobiliary ductal system development. PLoS Genet. 8, e1002754.
Desai, B.M., Oliver-Krasinski, J., De Leon, D.D., Farzad, C., Hong, N., Leach,
S.D., and Stoffers, D.A. (2007). Preexisting pancreatic acinar cells contribute to
acinar cell, but not islet beta cell, regeneration. J. Clin. Invest. 117, 971–977.
Dhawan, S., Georgia, S., Tschen, S.I., Fan, G., and Bhushan, A. (2011).
Pancreatic b cell identity is maintained by DNA methylation-mediated repres-
sion of Arx. Dev. Cell 20, 419–429.
Direnzo, D., Hess, D.A., Damsz, B., Hallett, J.E., Marshall, B., Goswami, C.,
Liu, Y., Deering, T., Macdonald, R.J., and Konieczny, S.F. (2012). Induced
Mist1 expression promotes remodeling of mouse pancreatic acinar cells.
Gastroenterology 143, 469–480.
Feldmann, G., Beaty, R., Hruban, R.H., and Maitra, A. (2007). Molecular ge-
netics of pancreatic intraepithelial neoplasia. J. Hepatobiliary Pancreat.
Surg. 14, 224–232.
Folias, A.E., Penaranda, C., Su, A.L., Bluestone, J.A., and Hebrok, M. (2014).
Aberrant innate immune activation following tissue injury impairs pancreatic
regeneration. PLoS ONE 9, e102125.
Gannon, M., Ables, E.T., Crawford, L., Lowe, D., Offield, M.F., Magnuson,
M.A., and Wright, C.V. (2008). pdx-1 function is specifically required in embry-
onic beta cells to generate appropriate numbers of endocrine cell types and
maintain glucose homeostasis. Dev. Biol. 314, 406–417.
Gao, T., McKenna, B., Li, C., Reichert, M., Nguyen, J., Singh, T., Yang, C., Pan-
nikar, A., Doliba, N., Zhang, T., et al. (2014). Pdx1 maintains b cell identity and
function by repressing an a cell program. Cell Metab. 19, 259–271.
Graf, T. (2011). Historical origins of transdifferentiation and reprogramming.
Cell Stem Cell 9, 504–516.
Gu, G., Dubauskaite, J., and Melton, D.A. (2002). Direct evidence for the
pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from
duct progenitors. Development 129, 2447–2457.
Guerra, C., Schuhmacher, A.J., Can˜amero, M., Grippo, P.J., Verdaguer, L.,
Pe´rez-Gallego, L., Dubus, P., Sandgren, E.P., and Barbacid, M. (2007).
Chronic pancreatitis is essential for induction of pancreatic ductal adenocarci-
noma by K-Ras oncogenes in adult mice. Cancer Cell 11, 291–302.
Cell Stem Cell
PerspectiveGuo, S., Dai, C., Guo, M., Taylor, B., Harmon, J.S., Sander, M., Robertson,
R.P., Powers, A.C., and Stein, R. (2013). Inactivation of specific b cell transcrip-
tion factors in type 2 diabetes. J. Clin. Invest. 123, 3305–3316.
Habbe, N., Shi, G., Meguid, R.A., Fendrich, V., Esni, F., Chen, H., Feldmann,
G., Stoffers, D.A., Konieczny, S.F., Leach, S.D., and Maitra, A. (2008). Sponta-
neous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by
acinar cell targeting of oncogenic Kras in adult mice. Proc. Natl. Acad. Sci.
USA 105, 18913–18918.
Habener, J.F., Kemp, D.M., and Thomas, M.K. (2005). Minireview: transcrip-
tional regulation in pancreatic development. Endocrinology 146, 1025–1034.
Harmon, J.S., Gleason, C.E., Tanaka, Y., Oseid, E.A., Hunter-Berger, K.K., and
Robertson, R.P. (1999). In vivo prevention of hyperglycemia also prevents glu-
cotoxic effects on PDX-1 and insulin gene expression. Diabetes 48, 1995–
2000.
Hart, A.W., Mella, S., Mendrychowski, J., van Heyningen, V., and Kleinjan, D.A.
(2013). The developmental regulator Pax6 is essential for maintenance of islet
cell function in the adult mouse pancreas. PLoS ONE 8, e54173.
Haumaitre, C., Barbacci, E., Jenny, M., Ott, M.O., Gradwohl, G., and Cere-
ghini, S. (2005). Lack of TCF2/vHNF1 in mice leads to pancreas agenesis.
Proc. Natl. Acad. Sci. USA 102, 1490–1495.
Haumaitre, C., Lenoir, O., and Scharfmann, R. (2008). Histone deacetylase
inhibitors modify pancreatic cell fate determination and amplify endocrine pro-
genitors. Mol. Cell. Biol. 28, 6373–6383.
Hesselson, D., Anderson, R.M., and Stainier, D.Y. (2011). Suppression of Ptf1a
activity induces acinar-to-endocrine conversion. Curr. Biol. 21, 712–717.
Holmstrom, S.R., Deering, T., Swift, G.H., Poelwijk, F.J., Mangelsdorf, D.J.,
Kliewer, S.A., and MacDonald, R.J. (2011). LRH-1 and PTF1-L coregulate an
exocrine pancreas-specific transcriptional network for digestive function.
Genes Dev. 25, 1674–1679.
Huang, S. (2009). Reprogramming cell fates: reconciling rarity with robustness.
BioEssays 31, 546–560.
Iype, T., Francis, J., Garmey, J.C., Schisler, J.C., Nesher, R., Weir, G.C.,
Becker, T.C., Newgard, C.B., Griffen, S.C., and Mirmira, R.G. (2005). Mecha-
nism of insulin gene regulation by the pancreatic transcription factor Pdx-1:
application of pre-mRNA analysis and chromatin immunoprecipitation to
assess formation of functional transcriptional complexes. J. Biol. Chem.
280, 16798–16807.
Jacquemin, P., Lemaigre, F.P., and Rousseau, G.G. (2003). The Onecut tran-
scription factor HNF-6 (OC-1) is required for timely specification of the
pancreas and acts upstream of Pdx-1 in the specification cascade. Dev.
Biol. 258, 105–116.
Jensen, J.N., Cameron, E., Garay, M.V., Starkey, T.W., Gianani, R., and Jen-
sen, J. (2005). Recapitulation of elements of embryonic development in adult
mouse pancreatic regeneration. Gastroenterology 128, 728–741.
Jonas, J.C., Sharma, A., Hasenkamp, W., Ilkova, H., Patane`, G., Laybutt, R.,
Bonner-Weir, S., and Weir, G.C. (1999). Chronic hyperglycemia triggers loss
of pancreatic beta cell differentiation in an animal model of diabetes. J. Biol.
Chem. 274, 14112–14121.
Jonsson, J., Carlsson, L., Edlund, T., and Edlund, H. (1994). Insulin-promoter-
factor 1 is required for pancreas development in mice. Nature 371, 606–609.
Jopling, C., Boue, S., and Izpisua Belmonte, J.C. (2011). Dedifferentiation,
transdifferentiation and reprogramming: three routes to regeneration. Nat.
Rev. Mol. Cell Biol. 12, 79–89.
Kamisawa, T., Tu, Y., Egawa, N., Ishiwata, J., Tsuruta, K., Okamoto, A., Hay-
ashi, Y., Koike, M., and Yamaguchi, T. (2002). Ductal and acinar differentiation
in pancreatic endocrine tumors. Dig. Dis. Sci. 47, 2254–2261.
Kaspi, H., Pasvolsky, R., and Hornstein, E. (2014). Could microRNAs
contribute to the maintenance of b cell identity? Trends Endocrinol. Metab.
25, 285–292.
Kawaguchi, Y., Cooper, B., Gannon, M., Ray, M., MacDonald, R.J., and
Wright, C.V. (2002). The role of the transcriptional regulator Ptf1a in converting
intestinal to pancreatic progenitors. Nat. Genet. 32, 128–134.
Klo¨ppel, G. (2011). Classification and pathology of gastroenteropancreatic
neuroendocrine neoplasms. Endocr. Relat. Cancer 18 (1), S1–S16.Kopinke, D., Brailsford, M., Shea, J.E., Leavitt, R., Scaife, C.L., and Murtaugh,
L.C. (2011). Lineage tracing reveals the dynamic contribution of Hes1+ cells to
the developing and adult pancreas. Development 138, 431–441.
Kopinke, D., Brailsford, M., Pan, F.C., Magnuson, M.A., Wright, C.V., andMur-
taugh, L.C. (2012). Ongoing Notch signaling maintains phenotypic fidelity in
the adult exocrine pancreas. Dev. Biol. 362, 57–64.
Kopp, J.L., Dubois, C.L., Schaffer, A.E., Hao, E., Shih, H.P., Seymour, P.A.,
Ma, J., and Sander, M. (2011). Sox9+ ductal cells are multipotent progenitors
throughout development but do not produce new endocrine cells in the normal
or injured adult pancreas. Development 138, 653–665.
Kopp, J.L., von Figura, G., Mayes, E., Liu, F.F., Dubois, C.L., Morris, J.P., 4th,
Pan, F.C., Akiyama, H., Wright, C.V., Jensen, K., et al. (2012). Identification of
Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism
for initiation of pancreatic ductal adenocarcinoma. Cancer Cell 22, 737–750.
Kordowich, S., Collombat, P., Mansouri, A., and Serup, P. (2011). Arx and
Nkx2.2 compound deficiency redirects pancreatic alpha- and beta-cell differ-
entiation to a somatostatin/ghrelin co-expressing cell lineage. BMC Dev. Biol.
11, 52.
Kubicek, S., Gilbert, J.C., Fomina-Yadlin, D., Gitlin, A.D., Yuan, Y., Wagner,
F.F., Holson, E.B., Luo, T., Lewis, T.A., Taylor, B., et al. (2012). Chromatin-tar-
geting small molecules cause class-specific transcriptional changes in
pancreatic endocrine cells. Proc. Natl. Acad. Sci. USA 109, 5364–5369.
Landsman, L., Parent, A., and Hebrok, M. (2011). Elevated Hedgehog/Gli
signaling causes beta-cell dedifferentiation in mice. Proc. Natl. Acad. Sci.
USA 108, 17010–17015.
Lenoir, O., Flosseau, K., Ma, F.X., Blondeau, B., Mai, A., Bassel-Duby, R., Rav-
assard, P., Olson, E.N., Haumaitre, C., and Scharfmann, R. (2011). Specific
control of pancreatic endocrine b- and d-cell mass by class IIa histone deace-
tylases HDAC4, HDAC5, and HDAC9. Diabetes 60, 2861–2871.
Li, W., Nakanishi, M., Zumsteg, A., Shear, M., Wright, C., Melton, D.A., and
Zhou, Q. (2014). In vivo reprogramming of pancreatic acinar cells to three islet
endocrine subtypes. eLife 3, e01846.
Lin, J.W., Biankin, A.V., Horb, M.E., Ghosh, B., Prasad, N.B., Yee, N.S., Pack,
M.A., and Leach, S.D. (2004). Differential requirement for ptf1a in endocrine
and exocrine lineages of developing zebrafish pancreas. Dev. Biol. 270,
474–486.
Lu, J., Herrera, P.L., Carreira, C., Bonnavion, R., Seigne, C., Calender, A., Ber-
tolino, P., and Zhang, C.X. (2010). Alpha cell-specific Men1 ablation triggers
the transdifferentiation of glucagon-expressing cells and insulinoma develop-
ment. Gastroenterology 138, 1954–1965.
Lynn, F.C., Skewes-Cox, P., Kosaka, Y., McManus, M.T., Harfe, B.D., and
German, M.S. (2007). MicroRNA expression is required for pancreatic islet
cell genesis in the mouse. Diabetes 56, 2938–2945.
Manfroid, I., Ghaye, A., Naye, F., Detry, N., Palm, S., Pan, L., Ma, T.P., Huang,
W., Rovira, M., Martial, J.A., et al. (2012). Zebrafish sox9b is crucial for hepa-
topancreatic duct development and pancreatic endocrine cell regeneration.
Dev. Biol. 366, 268–278.
Mansouri, A. (2012). Development and regeneration in the endocrine
pancreas. ISRN Endocrinol. 2012, 640956.
Mastracci, T.L., Wilcox, C.L., Arnes, L., Panea, C., Golden, J.A., May, C.L., and
Sussel, L. (2011). Nkx2.2 and Arx genetically interact to regulate pancreatic
endocrine cell development and endocrine hormone expression. Dev. Biol.
359, 1–11.
Matthaei, H., Schulick, R.D., Hruban, R.H., and Maitra, A. (2011). Cystic pre-
cursors to invasive pancreatic cancer. Nat Rev. Gastroenterol. Hepatol. 8,
141–150.
Miyamoto, Y., Maitra, A., Ghosh, B., Zechner, U., Argani, P., Iacobuzio-Dona-
hue, C.A., Sriuranpong, V., Iso, T., Meszoely, I.M., Wolfe, M.S., et al. (2003).
Notch mediates TGF alpha-induced changes in epithelial differentiation during
pancreatic tumorigenesis. Cancer Cell 3, 565–576.
Morris, J.P., 4th, Cano, D.A., Sekine, S., Wang, S.C., and Hebrok, M. (2010a).
Beta-catenin blocks Kras-dependent reprogramming of acini into pancreatic
cancer precursor lesions in mice. J. Clin. Invest. 120, 508–520.Cell Stem Cell 16, January 8, 2015 ª2015 Elsevier Inc. 29
Cell Stem Cell
PerspectiveMorris, J.P., 4th, Wang, S.C., and Hebrok, M. (2010b). KRAS, Hedgehog, Wnt
and the twisted developmental biology of pancreatic ductal adenocarcinoma.
Nat. Rev. Cancer 10, 683–695.
Offield, M.F., Jetton, T.L., Labosky, P.A., Ray, M., Stein, R.W., Magnuson,
M.A., Hogan, B.L., and Wright, C.V. (1996). PDX-1 is required for pancreatic
outgrowth and differentiation of the rostral duodenum. Development 122,
983–995.
Pan, F.C., Bankaitis, E.D., Boyer, D., Xu, X., Van de Casteele, M., Magnuson,
M.A., Heimberg, H., and Wright, C.V. (2013). Spatiotemporal patterns of multi-
potentiality in Ptf1a-expressing cells during pancreas organogenesis and
injury-induced facultative restoration. Development 140, 751–764.
Papizan, J.B., Singer, R.A., Tschen, S.I., Dhawan, S., Friel, J.M., Hipkens, S.B.,
Magnuson, M.A., Bhushan, A., and Sussel, L. (2011). Nkx2.2 repressor com-
plex regulates islet b-cell specification and prevents b-to-a-cell reprogram-
ming. Genes Dev. 25, 2291–2305.
Pierreux, C.E., Poll, A.V., Kemp, C.R., Clotman, F., Maestro, M.A., Cordi, S.,
Ferrer, J., Leyns, L., Rousseau, G.G., and Lemaigre, F.P. (2006). The transcrip-
tion factor hepatocyte nuclear factor-6 controls the development of pancreatic
ducts in the mouse. Gastroenterology 130, 532–541.
Pin, C.L., Rukstalis, J.M., Johnson, C., and Konieczny, S.F. (2001). The bHLH
transcription factor Mist1 is required to maintain exocrine pancreas cell orga-
nization and acinar cell identity. J. Cell Biol. 155, 519–530.
Poitout, V., and Robertson, R.P. (2008). Glucolipotoxicity: fuel excess and
beta-cell dysfunction. Endocr. Rev. 29, 351–366.
Poy, M.N., Eliasson, L., Krutzfeldt, J., Kuwajima, S., Ma, X., Macdonald, P.E.,
Pfeffer, S., Tuschl, T., Rajewsky, N., Rorsman, P., and Stoffel, M. (2004). A
pancreatic islet-specific microRNA regulates insulin secretion. Nature 432,
226–230.
Poy, M.N., Hausser, J., Trajkovski, M., Braun, M., Collins, S., Rorsman, P., Za-
volan, M., and Stoffel, M. (2009). miR-375 maintains normal pancreatic alpha-
and beta-cell mass. Proc. Natl. Acad. Sci. USA 106, 5813–5818.
Pre´vot, P.P., Simion, A., Grimont, A., Colletti, M., Khalaileh, A., Van den Steen,
G., Sempoux, C., Xu, X., Roelants, V., Hald, J., et al. (2012). Role of the ductal
transcription factors HNF6 and Sox9 in pancreatic acinar-to-ductal meta-
plasia. Gut 61, 1723–1732.
Prevot, P.P., Augereau, C., Simion, A., Van den Steen, G., Dauguet, N., Lemai-
gre, F.P., and Jacquemin, P. (2013). Let-7b and miR-495 stimulate differentia-
tion and prevent metaplasia of pancreatic acinar cells by repressing HNF6.
Gastroenterology 145, 668–678, e663.
Pullen, T.J., da Silva Xavier, G., Kelsey, G., and Rutter, G.A. (2011). miR-29a
and miR-29b contribute to pancreatic beta-cell-specific silencing of monocar-
boxylate transporter 1 (Mct1). Mol. Cell. Biol. 31, 3182–3194.
Puri, S., Akiyama, H., and Hebrok, M. (2013). VHL-mediated disruption of Sox9
activity compromises b-cell identity and results in diabetes mellitus. Genes
Dev. 27, 2563–2575.
Pylayeva-Gupta, Y., Lee, K.E., Hajdu, C.H., Miller, G., and Bar-Sagi, D. (2012).
Oncogenic Kras-induced GM-CSF production promotes the development of
pancreatic neoplasia. Cancer Cell 21, 836–847.
Rezania, A., Riedel, M.J., Wideman, R.D., Karanu, F., Ao, Z., Warnock, G.L.,
and Kieffer, T.J. (2011). Production of functional glucagon-secreting a-cells
from human embryonic stem cells. Diabetes 60, 239–247.
Rovira, M., Scott, S.G., Liss, A.S., Jensen, J., Thayer, S.P., and Leach, S.D.
(2010). Isolation and characterization of centroacinar/terminal ductal progeni-
tor cells in adult mouse pancreas. Proc. Natl. Acad. Sci. USA 107, 75–80.
Sancho, R., Gruber, R., Gu, G., and Behrens, A. (2014). Loss of Fbw7 repro-
grams adult pancreatic ductal cells into a, d, and b cells. Cell Stem Cell 15,
139–153.
Schaffer, A.E., Freude, K.K., Nelson, S.B., and Sander, M. (2010). Nkx6 tran-
scription factors and Ptf1a function as antagonistic lineage determinants in
multipotent pancreatic progenitors. Dev. Cell 18, 1022–1029.
Schaffer, A.E., Taylor, B.L., Benthuysen, J.R., Liu, J., Thorel, F., Yuan,W., Jiao,
Y., Kaestner, K.H., Herrera, P.L., Magnuson, M.A., et al. (2013). Nkx6.1 con-
trols a gene regulatory network required for establishing and maintaining
pancreatic Beta cell identity. PLoS Genet. 9, e1003274.30 Cell Stem Cell 16, January 8, 2015 ª2015 Elsevier Inc.Seymour, P.A., Freude, K.K., Tran, M.N., Mayes, E.E., Jensen, J., Kist, R.,
Scherer, G., and Sander, M. (2007). SOX9 is required for maintenance of the
pancreatic progenitor cell pool. Proc. Natl. Acad. Sci. USA 104, 1865–1870.
Seymour, P.A., Freude, K.K., Dubois, C.L., Shih, H.P., Patel, N.A., and Sander,
M. (2008). A dosage-dependent requirement for Sox9 in pancreatic endocrine
cell formation. Dev. Biol. 323, 19–30.
Shang, L., Hua, H., Foo, K., Martinez, H., Watanabe, K., Zimmer, M., Kahler,
D.J., Freeby, M., Chung, W., LeDuc, C., et al. (2014). b-cell dysfunction due
to increased ER stress in a stem cell model of Wolfram syndrome. Diabetes
63, 923–933.
Shi, C., and Hruban, R.H. (2012). Intraductal papillary mucinous neoplasm.
Hum. Pathol. 43, 1–16.
Shi, G., DiRenzo, D., Qu, C., Barney, D., Miley, D., and Konieczny, S.F. (2013).
Maintenance of acinar cell organization is critical to preventing Kras-induced
acinar-ductal metaplasia. Oncogene 32, 1950–1958.
Siveke, J.T., Lubeseder-Martellato, C., Lee, M., Mazur, P.K., Nakhai, H.,
Radtke, F., and Schmid, R.M. (2008). Notch signaling is required for exocrine
regeneration after acute pancreatitis. Gastroenterology 134, 544–555.
Solar, M., Cardalda, C., Houbracken, I., Martı´n, M., Maestro, M.A., De Medts,
N., Xu, X., Grau, V., Heimberg, H., Bouwens, L., and Ferrer, J. (2009). Pancre-
atic exocrine duct cells give rise to insulin-producing beta cells during embryo-
genesis but not after birth. Dev. Cell 17, 849–860.
Song, S.Y., Gannon, M., Washington, M.K., Scoggins, C.R., Meszoely, I.M.,
Goldenring, J.R., Marino, C.R., Sandgren, E.P., Coffey, R.J., Jr., Wright,
C.V., and Leach, S.D. (1999). Expansion of Pdx1-expressing pancreatic
epithelium and islet neogenesis in transgenic mice overexpressing transform-
ing growth factor alpha. Gastroenterology 117, 1416–1426.
Spijker, H.S., Ravelli, R.B., Mommaas-Kienhuis, A.M., van Apeldoorn, A.A.,
Engelse, M.A., Zaldumbide, A., Bonner-Weir, S., Rabelink, T.J., Hoeben,
R.C., Clevers, H., et al. (2013). Conversion of mature human b-cells into
glucagon-producing a-cells. Diabetes 62, 2471–2480.
Stoffers, D.A., Ferrer, J., Clarke, W.L., and Habener, J.F. (1997a). Early-onset
type-II diabetes mellitus (MODY4) linked to IPF1. Nat. Genet. 17, 138–139.
Stoffers, D.A., Zinkin, N.T., Stanojevic, V., Clarke, W.L., and Habener, J.F.
(1997b). Pancreatic agenesis attributable to a single nucleotide deletion in
the human IPF1 gene coding sequence. Nat. Genet. 15, 106–110.
Swales, N., Martens, G.A., Bonne´, S., Heremans, Y., Borup, R., Van de
Casteele, M., Ling, Z., Pipeleers, D., Ravassard, P., Nielsen, F., et al. (2012).
Plasticity of adult human pancreatic duct cells by neurogenin3-mediated re-
programming. PLoS ONE 7, e37055.
Talchai, C., Xuan, S., Lin, H.V., Sussel, L., and Accili, D. (2012). Pancreatic b
cell dedifferentiation as a mechanism of diabetic b cell failure. Cell 150,
1223–1234.
Thorel, F., Ne´pote, V., Avril, I., Kohno, K., Desgraz, R., Chera, S., and Herrera,
P.L. (2010). Conversion of adult pancreatic alpha-cells to beta-cells after
extreme beta-cell loss. Nature 464, 1149–1154.
von Figura, G., Fukuda, A., Roy, N., Liku, M.E., Morris Iv, J.P., Kim, G.E., Russ,
H.A., Firpo, M.A., Mulvihill, S.J., Dawson, D.W., et al. (2014a). The chromatin
regulator Brg1 suppresses formation of intraductal papillary mucinous
neoplasm and pancreatic ductal adenocarcinoma. Nat. Cell Biol. 16, 255–267.
von Figura, G., Morris, J.P., 4th, Wright, C.V., and Hebrok, M. (2014b). Nr5a2
maintains acinar cell differentiation and constrains oncogenic Kras-mediated
pancreatic neoplastic initiation. Gut 63, 656–664.
Vortmeyer, A.O., Huang, S., Lubensky, I., and Zhuang, Z. (2004). Non-islet
origin of pancreatic islet cell tumors. J. Clin. Endocrinol. Metab. 89, 1934–
1938.
Wang, Z., York, N.W., Nichols, C.G., and Remedi, M.S. (2014). Pancreatic b
cell dedifferentiation in diabetes and redifferentiation following insulin therapy.
Cell Metab. 19, 872–882.
Wilcox, C.L., Terry, N.A., Walp, E.R., Lee, R.A., and May, C.L. (2013). Pancre-
atic a-cell specific deletion of mouse Arx leads to a-cell identity loss. PLoS
ONE 8, e66214.
Wilson,M.E., Scheel, D., andGerman,M.S. (2003). Gene expression cascades
in pancreatic development. Mech. Dev. 120, 65–80.
Cell Stem Cell
PerspectiveXu, X., D’Hoker, J., Stange´, G., Bonne´, S., De Leu, N., Xiao, X., Van de Cas-
teele, M., Mellitzer, G., Ling, Z., Pipeleers, D., et al. (2008). Beta cells can be
generated from endogenous progenitors in injured adult mouse pancreas.
Cell 132, 197–207.
Xu, C.R., Cole, P.A., Meyers, D.J., Kormish, J., Dent, S., and Zaret, K.S. (2011).
Chromatin ‘‘prepattern’’ and histone modifiers in a fate choice for liver and
pancreas. Science 332, 963–966.
Yang, Y.P., Thorel, F., Boyer, D.F., Herrera, P.L., and Wright, C.V. (2011).
Context-specific a- to-b-cell reprogramming by forced Pdx1 expression.
Genes Dev. 25, 1680–1685.
Ying, H., Kimmelman, A.C., Lyssiotis, C.A., Hua, S., Chu, G.C., Fletcher-San-
anikone, E., Locasale, J.W., Son, J., Zhang, H., Coloff, J.L., et al. (2012). Onco-genic Krasmaintains pancreatic tumors through regulation of anabolic glucose
metabolism. Cell 149, 656–670.
Zhang, H., Ables, E.T., Pope, C.F., Washington, M.K., Hipkens, S., Means,
A.L., Path, G., Seufert, J., Costa, R.H., Leiter, A.B., et al. (2009). Multiple, tem-
poral-specific roles for HNF6 in pancreatic endocrine and ductal differentia-
tion. Mech. Dev. 126, 958–973.
Zhou, Q., Law, A.C., Rajagopal, J., Anderson, W.J., Gray, P.A., and Melton,
D.A. (2007). A multipotent progenitor domain guides pancreatic organogen-
esis. Dev. Cell 13, 103–114.
Zhou, Q., Brown, J., Kanarek, A., Rajagopal, J., andMelton, D.A. (2008). In vivo
reprogramming of adult pancreatic exocrine cells to beta-cells. Nature 455,
627–632.Cell Stem Cell 16, January 8, 2015 ª2015 Elsevier Inc. 31
